Brief: Biovaxys Bioproduction Partner Wuxi Biologics Completes Synthesis Of Recombinant Sars-Cov-2 S-Proteins For Bvx-0320 And Covidth Programs
14/09/2021 08:06
Sept 14 (Reuters) - Biovaxys Technology Corp BIOV.CD :
* BIOVAXYS BIOPRODUCTION PARTNER WUXI BIOLOGICS COMPLETES
SYNTHESIS OF RECOMBINANT SARS-COV-2 S-PROTEINS FOR BVX-0320 AND
COVIDTH PROGRAMS
Source text for Eikon: ID:nCNWSvnvBa
Further company coverage: BIOV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biovaxys Technology
See all newsBrief: Biovaxys Appoints Former Sanofi Vaccines Executive To Board Of Directors
Brief: Biovaxys Announces Life Offering
Brief: Biovaxys And Horizon Technology Finance Execute Amendment To Asset Purchase Agreement
Brief: Biovaxys And Horizon Technology Finance Execute Amendment To Asset Purchase Agreement
Brief: Biovaxys Announces Consolidation And Concurrent Brokered Private Placement Offering For Gross Proceeds Of Up To $3,000,000